Haleon

Update in progress

HLN (NYSE)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Haleon plc and its subsidiaries develop, manufacture, and sell consumer healthcare products across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It offers oral health products under Sensodyne, Polident, Parodontax, and Biotene; vitamins and supplements under Centrum, Emergen-C, and Caltrate. It also provides OTC medicines for respiratory relief (Theraflu, Flonase), pain relief (Voltaren, Panadol, Advil), and digestive health (TUMS, ENO) and Fenistil.

Company score

Sentiment: 2.45; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.60; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 1.86; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.82; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.93; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 1.69; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive